COMBINED USE OF QSOFA SCORE, LACTATE AND NLR AS AN EARLY PREDICTIRE OF SPESIS IN PAINENTS PRESENTING TO EMERGENCY DEPARTMENT

By

Dr. RAJESH KUMAR

Dissertation submitted to

BLDE (Deemed to be University) Vijayapur, Karnataka



In partial fulfillment of the requirements for the degree of

DOCTOR OF MEDICINE IN

EMERGENCY MEDICNE

Under the guidance of

Dr.RAVI. B. PATIL

PROFESSOR
DEPARTMENT OF EMERGENCY MEDICNE

BLDE (Deemed to be University)
SHRI B.M.PATIL MEDICAL COLLEGE

HOSPITAL & RESEARCH CENTRE, VIJAYAPUR

KARNATAKA

2020

DocuSign Envelope ID: 4440D605-CACD-4AB4-940D-FF9106780E7A

"Combined Use of qSOFA Score, Lactate and NLR as an early predictor of sepsis in patients presenting to Emergency department"

DOCTOR OF MEDICINE

IN

EMERGENCY MEDICINE

LIST OF CONTENTS

Sl No		Page No	
1		11	
2		16	
3		AIMS & OBJECTIVES	29
4		METHODOLOGY	32
5		RESULTS	35
6		DISCUSSION	60
7		STRENGTHS & LIMITATIONS	65
8		CONCLUSION	66
9		BIBLIOGRAPHY	67
10		ANNEXURES	
	I.	ETHICAL CLEARANCE CERTIFICATE	
	II.	PATIENT CONSENT FORM	74
	III.	PROFORMA	75
	***		79
	IV.	FORMULA TO DERIVE NLR	82
	V.	MASTER CHART	83
1			ı

LIST OF TABLES

38
38
42
46
50
51
54
_

LIST OF FIGURES

Sl No.	. FIGURE			
1.	FLOW DIAGRAM OF RECRUITMENT OF CASES			
2.	DISTRIBUTION OF CASES BY AGE AND GENDER	39		
3.	OVERALL, GENDER DISTRIBUTION OF CASES	40		
4.	DIAGNRAMMATIC REPRESENTATION OF AGE DISTRIBUTION BETWEEN SURVIVOR AND NONSURVIVOR GOUPS	43		
5.	DIAGRAMMATIC REPRESENTATION OF GENDER DISTRIBUTION BETWEEN SURVIVOR AND NONSURVIVOR GOUPS	44		
6.	HISTOGRAM SHOWING THE DIFFERENCE IN qSOFA SCORE AT ADMISSION BETWEEN SURVIVOR AND NONSURVIVOR GROUPS			
7.	HISTOGRAM SHOWING GENDER DISTRIBUTION AMONG qSOFA CASES REQUIRING VASOPRESSOR			
8.	HISTOGRAM SHOWING FREQUENCY DISTRIBUTION OF SITES OF SEPSIS AMONG SURVIVOR AND NONSURVIVOR GROUPS			
9.	ROC CURVE FOR NLR AS A DIAGNOSTIC MARKER FOR EARLY SEPSIS			
10.	ROC CURVE OF qSOFA, NLR AND LACTATE AS DIAGNOSTIC MARKER FOR EARLY SEPSIS	58		

ABBREVIATIONS

ED	Emergency Department		
SS	Severe sepsis		
SIRS	Systemic inflammatory response syndrome		
qSOFA	Quick Sequential Organ function assessment		
GCS	Glasgow Coma Scale		
SBP	Systolic Blood Pressure		
MAP	Mean arterial pressure		
RR	Respiratory Rate		
TLC	Total leucocyte count		
DLC	Differential leucocyte count		
NLR	Neutrophil: Lymphocyte ratio		
ANC	Absolute Neutrophil Count		
ALC	Absolute Lymphocyte Count		
SD	Standard deviation		
CI	Confidence interval		
S	Survivor group		
NS	Non survivor group		
Sn	Sensitivity		
Sp	Specificity		
ROC	Receiver Operator Characteristic		
PDH	Pyruvate Dehydrogenase		

INTRODUCTION

Sepsis is the presence of life-threatening organ dysfunction caused by a dysregulated response of body to infection. Sepsis -3 is the new term adapted in 2016 task force convened by National societies including the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM) to replace severe sepsis and septic shock. [Singer M 2016] Patients with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pressure (MAP) of > 65mmHg and serum lactate level > 2 mmol/L (>18mg/dL) in absence of hypovolemia. The criteria to identify poor prognosis in sepsis is defined as presence of at least 2 of the following clinical criteria that together constitute a new bedside clinical score termed quick SOFA (qSOFA): respiratory rate (RR) of > 22/min, altered sensorium (GCS < 15) or systolic blood pressure (SBP) of < 90 mmHg. This is a rapid unaided, noninvasive, easy to perform assessment which can be performed anywhere within hospital like in emergency department, ICU and general hospital ward settings. Sepsis -3 is a sever disease with global burden of 48.9 million cases and 11 million sepsis-related mortality. Annual incidence of sepsis is approximately 19.4 million cases per year out of which 14.1 million require hospitalization. Mortality rate from sepsis ranges between 25% and 30% for severe sepsis and 40% and 70% for septic shock. [Lever A 2007] It has been reported to be the second leading cause of death in non-coronary intensive care units, and overall, it is the tenth leading cause of death. Sepsis is classifying into two phases on the basis of duration - Early phase and late phase. Early phase is initial 5 days of illness followed by the late phase. [Rich'e F 2015] Singer et al stated that early recognition of sepsis is essential for reducing the

high mortality and morbidity rate in patients with suspected infection presented to ED.

[Singer et al 2015]

Researchers are always in search of definite clinical and laboratory parameters to consider them as biomarkers that could be accurate and reproducible and should be used as a diagnostic tool for disease identification or abnormal conditions associated with disease as well as for staging disease, its prognosis and response to intervention. There are numerous cellular processes involved in sepsis hence finding a reliable and specific diagnostic biomarker is a challenging task for scientists till date. More than 1000 different molecules have been identified and suggested to be used as useful biomarkers of sepsis in past decade. The hematological parameters supposed to be used as biomarkers are under study like TLC, ANC, ALC, NLR, Platelet count (PLC), Platelet: Lymphocyte ratio (PLR), Erythrocyte Sedimentation Rate (ESR) and Peripheral blood smear examination for toxic granules and vacuoles. Biochemical markers studied for sepsis and sepsis related complications include ABG, lactate, interleukins, cytokines, Procalcitonin, C-reactive protein, Angiopoietins, Endocans, leukocyte surface antigen CD64, triggering receptor expressed on myeloid cells 1(TREM-1), Circulating cell – free DNA (cf-DNA), Programmed cell death receptor -1 (PD-1), B and T-lymphocyte attenuator (BTLA), Cytotoxic T-lymphocyte antigen -4 (CTLA-4) etc. The individual role of these molecules in relation to sepsis is well explained in several studies but no one had proven effectively as diagnostic or prognostic tool. [Faix JD 2013]

Blood culture is the gold standard microbiological investigation used for diagnostic conformation since long ago but the major drawback is its time consumption (3-5days)

and false negative result when patient has previously received antibiotics. This is a major concern for clinicians while handling a case with suspected infection in ED during which patients' morbidity and mortality progresses rapidly.

As per the sepsis 3 guideline, quick sequential organ failure assessment (qSOFA) score has become an important clinical tool that can be utilized at bedside for identification of sepsis and predict mortality. It gives an alarm meant by "do not loose time".

The qSOFA score consists of three clinical elements: hypotension (SBP < 90 mmHg), tachypnea (RR >22/minute) and altered mental status (Glasgow coma scale <15 points). Total score ranges between 0 and 3. This score was originally proposed as a screening tool to identify patients with suspected infection outside the intensive care unit (ICU) who are at a high risk for poor outcomes, including hospital mortality in accordance with the new sepsis-3 definition. [Singer M 2016] However, the predictive accuracy of qSOFA might be limited according to recent studies, particularly in the initial evaluation of high-risk patients in the ED. In the original qSOFA study, ED populations were not analyzed separately from the larger study population, and the poor discriminative ability of qSOFA has raised concerns about its role for ED patients requiring early recognition and timely intervention. An extreme variation in a single physiological parameter is not considered to be positive in the qSOFA system. However, as highlighted by Williams et al., one limitation of the new definition is the poor sensitivity of the qSOFA scoring system, which likely excludes its use as a screening tool for early sepsis, the stage in which treatment is most effective. [Williams]

The NLR (neutrophil lymphocyte ratio) is one of the simplest and easily available hematological parameters that can be utilized for subcategorization of patients on severity scale as well as an independent prognostic factor for disease evaluation. Farkas J had stated in his study that several multidisciplinary studies included NLR as prognostic factor, for example: in traumatic brain injury, acute pancreatitis, acute and complicated appendicitis, colorectal malignancy, Head and neck malignancy, intracranial hemorrhage, pulmonary embolism etc. NLR can also be used to assess the severity of sepsis, degree of bacteremia and to differentiate between septic and cardiogenic shock. The values of NLR ratio will be presented in range which is useful to categorize physiological stress. This can also be used as an inflammatory biomarker. [Farkas J] Neutrophil-to-lymphocyte ratio is an easily derived parameter obtained from routine hemogram by dividing absolute neutrophil count to absolute lymphocyte count. The ratio suggests the vascular response against altered hemodynamic milieu in critically ill patients. Several studies reported sensitivity of NLR in prognosis of disease, however its role in early diagnosis of sepsis and septic shock is under investigation.

Suetrong B described in their study that lactate is a metabolite formed during anaerobic glycolysis and is associated with sepsis and tissue hypoxia. Hyperlactatemia and lactic acidosis are common in patients with septic shock and are associated with significant morbidity and mortality. [Suetrong B] As a result, the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) has included hyperlactatemia over 2 mmol/L in the revised definition of septic shock. [Suetrong B]

Kraut JA described that lactic acidosis results from the accumulation of lactate and protons in the body fluids and is often associated with poor clinical outcomes. [Kraut JA] According to Rivers E and Jansen TC, lactate is a parameter of global tissue hypoperfusion and is essential in identifying patients with "cryptic" shock who require focused early goal-directed therapy (EGDT). [Rivers E, Jansen TC] Since sepsis had a complex pathophysiology which include several cellular and molecular response going on simultaneously in an additive manner to flare the response rapidly, looking for an individual biomarker is not going to be much helpful but the combination of several biomarkers may help in a better way. [Biron MB 2015] The lacunae observed after extensive search in published articles through Google search engine and PubMed database, is lack of any single and or panel of clinical and laboratory tools in spite of discovery of thousands of biomarkers with proven association with sepsis, that could accurately identify sepsis in minimum time and should be rapid, time saving and minimally invasive so that clinicians can start Goal Directed therapy within time to improve patient outcome.

This study is designed to observe the role of qSOFA score, NLR and Lactate in patients with suspected infection, its early diagnostic implication and its correlation with qSOFA in predicting early sepsis, mortality and critical care requirements in patients presented to emergency department.

REVIEW OF LITERATURE

Sepsis is a complex, dynamic and resource-demanding clinical entity frequently encountered in critical care settings. Sepsis was first mentioned in Hippocrates' writings and is derived from the Greek word "sepo," which means "I rot." The documented use of term Sepsis at first time was about 2700 years ago found in Homer's poems. [Gyawali B 2019]

The modern definition for sepsis was given by Hugo Schottmuller in 1914 as "sepsis is present if a focus has developed from which pathogenic bacteria, constantly or periodically invade the blood stream in such a way that this causes subjective and objective symptoms". The first consensus definition of sepsis was founded by Roger Bone and his colleagues in SCCM-ACCP conference organized in 1991 "as the presence of both suspected infection and two of the four criteria of the systemic inflammatory response syndrome (SIRS)". [ACCP1991]

Sepsis may have been perceived with a humbler eye a couple of decades ago, but now the scenario has changed. Once easily treatable with antimicrobials, several common microorganisms have camouflaged themselves with a diverse armamentarium of antimicrobial resistance, belittling the available antibiotic arsenal. No longer being a local or regional public health problem, sepsis now demands a global perspective on an urgent basis. What makes the situation even worse in developing countries like India has limitations of resources (drugs, infrastructure and human resources). The high prevalence of HIV/AIDS and delayed referrals pose further challenges to healthcare providers in developing countries.

From past two decades the significant advances in pathobiology of sepsis with better understanding of cellular response, biochemistry, immunology and morphology, changes in circulation and organ function have led to the changes in the definition of sepsis and its progressing events. The term sepsis defined by Roger Bone and his colleagues is known as Sepsis – 1 which leads to the onset of Systemic inflammatory response syndrome (SIRS). The diagnostic criteria for SIRS were defined by presence of > 2 criteria of tachycardia (hear rate > 90 beats/min), tachypnea (respiratory rate > 20 breaths/min), fever or hypothermia (temperature > 38 or $< 36^{\circ}$ C) and leucocytosis, leucopenia or bandemia (WBC > 1200/cmm, < 4000/cmm or bandemia > 10%). With time in 2001, a task force (2001) [Marik PE] expanded the list of diagnostic criteria, resulting in the introduction of Sepsis-2 and defined it as an individual must have at least 2 SIRS criteria and a confirmed or suspected infection. [Bone RC] The progression of sepsis is further named as severe sepsis and septic shock. Severe sepsis is defined as sepsis complicated by organ dysfunction which could progress to septic shock.

Septic shock is defined as unrecovered hypotension despite adequate fluid replacement in the Surviving Sepsis Campaign (SSC) Guidelines. Sepsis-induced arterial hypotension is defined as a systolic blood pressure (SBP) < 90 mmHg or mean arterial pressure (MAP) < 70 mmHg or a SBP decrease > 40 mmHg or less than two standard deviations below normal for age in the absence of other causes of hypotension.

[Dellinger RP] In 2016, SCCM/ESICM had proposed Sepsis-3 in which sepsis is defined as life threatening organ dysfunction caused by a dysregulated host response to infection.[Singer M 2016]

Patho-physiologically the host immune response to sepsis is characterized by two sequential stages: first is a hyper-inflammatory response and second is compensatory anti-inflammatory response syndrome (CARS). The hyper-inflammatory response is also known as cytokine storm in which two events are going on simultaneously: one is release of proinflammatory cytokines from activated innate immune system to overcome underlying infection and recruitment of members of adaptive immune response to mount an intense immune response. This event is followed by systemic deactivation of immune system and restoration of homeostasis. Lactic acidosis induced acidic milieu depresses the cardiac function and decreases vasopressor response. Roughly 9% of patients with sepsis progress to severe sepsis out of which 3% experience septic shock, accounting for 10% of admissions to ICU. [Singer 2016] Organ failure occurs in 33.6% of the patients with sepsis. Severe sepsis carries estimated 30-50% mortality. 70% of the patients with three or more organ failures die. Those who survive sepsis have been found to have a lower quality of life compared to the general population. [Singer M 2016, Zahorec R 2001, Jiang I 2018, Ljungstrom L 2017, Riche F 2015, Salciocioli]

Diagnosis of sepsis include clinical and laboratory examination either individually or in combination in the form of criteria, scores, bundle or panel. The most important clinical parameters that are altered severely in sepsis are RR, HR, Blood pressure, temperature and altered sensorium. The criteria for diagnosis and prognosis of sepsis evolved are SIRS, Severe sepsis Campaign, Sepsis bundle, APACHE II, SOFA, GCS, qSOFA and many more. Thousands of molecular markers are studied in sepsis among which White blood cell count, Absolute neutrophil count, Absolute lymphocyte count,

Neutrophil:Lymphocyte ratio, Platelet count, Platelet: Lymphocyte ratio, lactate, cytokines, chemokines, acute phase reactants, PCT, CRP, blood culture and many more. However, in past two decades there is no consensus developed yet an accurate diagnostic and prognostic marker for sepsis.

Studies describe significance of SOFA and qSOFA in evaluating the prognosis in sepsis and its comparison with other severity scores like SIRS. Patients who fulfill SOFA score have a predicted mortality of ≥10%. However, the complexity of calculation of score, the lack of requisite data for many patients and concerns that it may result in late identification relative to other methods raise the possibility that its use according to the Sepsis-3 method may prove impractical in clinical practice.

Recognizing these practical limitations, the 2016 SCCM/ESICM task force described a simplified method termed "quick SOFA" to facilitate easier identification of patients potentially at risk of dying from sepsis. [Annexure II] This score is a modified version of the SOFA known as qSOFA that consists of only three components each allocated one point. It was found that qSOFA is a good prognostic marker for mortality and multi organ failure in septic patients but is not a good diagnostic marker for sepsis. [Singer M2015]

Williams et al. highlighted the poor sensitivity of the qSOFA scoring system in diagnosis of Sepsis-3, which likely excludes its use as a screening tool for early sepsis, the stage in which treatment is most effective. [Williams] Rodriguez et al showed that qSOFA is equal to or better than SIRS in predicting the critical illness in septic patients admitted to ED. [Rodriguez et al] Data from New Zealand intensive care society showed that interventions like intubation, sedation and mechanical ventilation

can interfere with the validity and accuracy of qSOFA score among critically ill patients. [Raith EP et al, Peirovifar A et al]. Though APACHE II, SOFA and SIRS criteria were followed widely since long time for prognosis of sepsis but due to limitations of time constraint, data availability and complexity of scoring these criteria are not adequate in early phases of sepsis where qSOFA will be the clinical diagnostic criteria of choice.

Among biochemical markers for diagnosis of sepsis most studied one is serum lactate level. Lactate is important source of energy, particularly during starvation. It also contributes to acidic environment by converting to lactic acid. Next, lactate is converted to bicarbonate and becomes a main source of alkalemia under normal conditions. Lactate of 1,400–1,500 mmol/L per day is formed from the reduction of pyruvate which is generated largely by anaerobic glycolysis. In tissue hypoxia, lactate is overproduced by increased anaerobic glycolysis. Lactate clearance typically occurs in the liver (60%), followed by the kidney (30%) and to a lesser extent by other organs (heart and skeletal muscle). [Jeppesen JB]

The mortality rate of septic patients with hyperlactatemia (≥4 mmol/L) is 30%, with hypotension alone is 36.7% and both hypotension and hyperlactatemia is 46.1%.

[Levy MM] Lee SM et al reported significantly higher acute hospital mortality in septic patients with hyperlactatemia than with lower serum lactate level. [Lee SM] Blood lactate levels can be easily and quickly determined hence these have been used as a surrogate of tissue hypoperfusion in critically ill patients admitted to ED or to ICU. Indeed, increased blood lactate levels have been used to identify critically ill patients at high risk of death even before the development of hemodynamic instability,

i.e., cryptic shock, as well as to trigger resuscitation. [Rady MY] Therefore, the early detection of septic shock based on a new definition is very important because early management of infection can reverse lactic acidosis and shock status.

Among hematological markers, recently NLR become a diagnostic tool of choice because of rapid and easy availability of test and high sensitivity and specificity in early diagnosis of sepsis. It is a ratio of absolute neutrophil to lymphocyte count which can be easily calculated from WBC differential counts. It ranges between 00 to 100 and a normal NLR is roughly falls within 1-3. The rise in NLR will indicate about underlying hypoxia any type of physiological or pathological stress. Zahorec R observed that NLR increases rapidly following acute physiologic stress (<6 hours). This prompt response time may make NLR a better reflection of acute stress than other hematological parameters. Interpretation of NLR depends on clinical context. Critically ill patients may have NLR > 9 which sometimes reach upto 100. NLR interpretation is considerably influenced in clinical context. For example, inflammatory disorders may tend to elevate NLR more than non-inflammatory disorders. Thus, a patient with sepsis and an NLR of 15 might not be tremendously ill, whereas a patient with a pulmonary embolism and an NLR of 15 is more worrisome. Jiang J et al had mentioned in their article that there are literatures flooded with studies using the NLR for everything from sepsis to cancer to restless leg syndrome but none of the studies used NLR along with qSOFA as a tool for early predictor of sepsis and to assess the disease severity. [Jiang J]

Farkas Jet al described studies that evaluated the ability of NLR to detect bacteremia, mostly in heterogeneous populations of patients presenting to ED however its

performance is poor. Meta-analysis shows that with a cutoff of ~10, NLR has a sensitivity of 72% and specificity of 60%. [Farkas J]

NLR has proven more useful in comparison to low or high white blood cell count (WBC) alone in sepsis when the two are directly compared. Ultimately, NLR may be a logical replacement for the WBC. In some situations, NLR is competitive with more expensive biomarkers (e.g., procalcitonin, lactate). Within specific clinical contexts (e.g., pancreatitis, pulmonary embolism), NLR may have surprisingly good prognostic value.

Studies show that NLR had similar performance compared to lactate or Procalcitonin. The sensitivity of NLR in relation to cut off value was also studied in various researches and it was found that a cutoff of 3 had higher sensitivity for sepsis than any other test (95%). Thus, a normal NLR (<3) argues against sepsis. NLR of > 10 support a diagnosis of sepsis. Intermediate values (3-10) fall within a grey zone.

Though NLR is a novel marker that evolved in last few years as a diagnostic and prognostic marker to differentiate between inflammatory versus non-inflammatory critical illness, between infectious and non-infectious critical diseases and indicator of poor prognosis with rise in its trend in time. This marker is also not exempted from few limitations.

Jiang J described the limitation of NLR indication in sepsis in their study as performance of the NLR for bacteremia among undifferentiated patients is limited due to the heterogeneous nature of this population. Many patients have severe physiologic stress (with elevated NLR) without bacteremia. Alternatively, some patients with bacteremia tolerate this surprisingly well and aren't very ill. In short, it's unrealistic to

expect NLR to perform well in this context. This isn't a failure of the test itself, but rather it represents a failure to apply the test appropriately. [Jiang I]

Limitations in NLR interpretation is multifactorial. Farkas et al had mentioned in detail about them. These factors include administration of exogenous steroid that increase margination of peripheral pool of neutrophils and hence increase the NLR in absence of bacteremia. Patients having active hematological disorders like leukemia, cytotoxic chemotherapy or Granulocyte colony stimulating factor (G-CSF) may affect white blood cell count and its differentiation leading to abnormally high or low NLR. In addition to that patients with advanced AIDS and chronic lymphopenia might be expected to have a higher baseline NLR. Ljungstrom et al evaluated the performance of several markers among a population of 1,572 patients admitted to ED with a clinical suspicion of sepsis. [Ljungstrom et al]

As discussed above in detail, no single test is found to be effective and better than other when early and accurate diagnosis as well as prognosis of sepsis is concerned. Several studies are performed to describe relationship of NLR with timing of death. Rich'e Fin a recent study showed a reversed NLR evolution according to the timing of death, whereas Salciccioli J. D. suggested no association between level of NLR and sepsis related mortality. [Rich'e F, Salciccioli J D] Consequently, the clinical usefulness of NLR in patients with sepsis is therefore still a matter of ongoing controversy and this question deserves further investigation.

Liu X et al were stated in their study the NLR levels of the patients with positive blood culture were significantly higher than the ones with negative blood culture (22.65

(IQR, 12.60 to 36.93) versus 14.66 (8.15 to 25.62), P = 0.000). Although the median length of stay in the hospital was similar between survivors and non-survivors (P = 0.468), the median length of stay in the ICU was significantly longer in non-survivors (P = 0.468). [Liu X] The NLR measured at the time of admission to ICU was associated with 28-day mortality and correlated well with disease severity, according to APACHE II score. NLR was able to accurately stratify patients in terms of short-term mortality. These findings remained robust after adjusting for several potential covariates, suggesting that increased NLR was independently associated with unfavorable outcome in patients with sepsis. The strength of the NLR is the possibility of implementing this parameter simply by using already available biomarkers (neutrophil count and lymphocyte count). Therefore, this ratio is easy to integrate in clinical practice and is cost effective.

Younan D et al compared in their study between demographic data, injury mechanism and severity (ISS) score, NLR at admission and at 24 and 48 hours and organ failure data. They describe their result for NLR patterns during the first 48 hours by dividing it into two trajectories identified by applying factor and cluster analysis to longitudinal measures. Statistical analysis shows 36% patients with Trajectory 1 had a mean NLR at admission of 3.6, which increased to 14.7 at 48 hours. 64% patients in Trajectory 2 had a mean NLR at admission of 8.5 which decreased to 6.6 at 48 hours. Mean NLR was different between the two groups at all three time points. Models adjusted for age, gender and ISS showed that trajectory 1 were more likely to have organ failure and degree of AKI than in Trajectory 2. In all cases, the estimated associations were higher among men vs. women, and all were significant among men, but not in women. They

conclude that Trauma patients with an increasing NLR trajectory over the first 48 hours had increased risk, number and severity of organ failures. [Younan D] Soulaiman et al had studied NLR among poly trauma patients and stated that in contrast to the widespread activation of neutrophils post-injury, the fall in total lymphocyte levels usually occurs in response to multiple traumas. The prognostic value of NLR had already studied in the diagnosis of familial Mediterranean fever, in acute appendicitis in relation to leucocytosis and estimated in non-traumatic disorders with higher sensitivity. Hence NLR can potentially be used as an early indicator of inflammatory homeostasis derailment in patients with tissue injury. They concluded that elevated NLR during the first 24 h of admission (day 1) has high predictive power for overall survival during the first 30 days after trauma, but it was not independent of other factors. [Soulaiman et al]

Connor H and Foucher CD, studied lactate level and its sources in human body.

Lactate is produced normally by skin, red cells, brain tissue, muscles and gastrointestinal tract. Lungs can produce lactate during acute lung injury without tissue hypoxia, and leukocytes generate lactate during phagocytosis or when activated in sepsis. Normally lactate is produced in excess by about 20 mmol/kg/day, which enters the bloodstream. [Connor H, Foucher CD]

Lactate is metabolized by liver and kidneys either by direct oxidation or as a source of glucose. According to Levy B lactate can be transformed into oxaloacetate or alanine via pyruvate pathway or can be utilized directly by periportal hepatocytes (60%) to produce glycogen and glucose (neoglycogenesis and neoglucogenesis; Cori cycle).

30% of lactate metabolism is done by kidneys in which the cortex classically acting as

metabolizer by neoglucogenesis and medulla as a producer of lactate. [Levy B] described the role of lactate in inflammation as it can modulate inflammation and promote immune tolerance. [Garcia-Alvarez M, Sun S] Sun S and Nasi A observed that lactate increases cellular production of anti-inflammatory cytokines such as interleukin-10. [Sun S and Nasi A] On the other hand Errea A and Husain Z stated that it reduces the activities of pro-inflammatory cytokines such as IL-12, macrophages, natural killer cells, and tumor necrosis factors. [Errea A, Husain Z] According to Mahnensmith RL and Malo ME in acute tissue ischemia, ischemiainduced lactic acid formation is an important cellular response which is activated by the plasma membrane sodium proton exchanges. [Mahnensmith RL, Malo ME] Sun S and Regli L stated that it increases intracellular sodium, and it leads to calcium overload via calcium-sodium exchange and inducing cell death. [Sun S and Regli L] According to Sikes PJ and Wu D in the setting of sepsis related lactic acidosis, animals which pretreated with sodium-proton exchanger blockers develop less hemodynamic instability and better survival compared with non-treated control groups. [Sikes PJ, Wu D] Suetrong B and Herbertson MJ in their studies mentioned that in sepsis and septic shock state, this critical oxygen extraction ratio is decreased to 50% or less so that lactic acid formation increases at oxygen deliveries that would normally be sufficient to meet the aerobic oxygen demand. [Suetrong B, Herbertson MJ] According to Suetrong B and Garcia-Alvarez M, microcirculatory dysfunction, which impairs oxygen delivery to the tissues, and mitochondrial dysfunction, which impairs oxygen utility, occur in patients with sepsis so that, even in an adequate oxygenation, anaerobic metabolism occurs and pyruvate is shunted toward lactate

production. [Suetrong B,Garcia-Alvarez M] Suetrong B and Levraut J found that reduced lactate clearance enhanced hyperlactatemia. In sepsis patients whose vital signs were stable, hyperlactatemia might be induced by the dysfunction of hepatic lactate clearance, which is primarily due to pyruvate dehydrogenase (PDH) inhibition. [Suetrong B, Levraut J] Levy B stated that in patients with sepsis and low-flow state, chronic liver disease further compromises lactate clearance. PDH converts pyruvate into acetyl-CoA, allowing pyruvate to enter the mitochondria. PDH activity was decreased in patients with septic muscle and is restored by dichloroacetate thus decreases hyperlactatemia in patients with sepsis. [LevyB] Foucher CD stated that regardless of the source, increased lactate levels have been associated with worse outcomes. Lactic acidosis can cause a reduction of cardiac contractility and vascular hypo-responsiveness to vasopressors through various mechanisms. It is a precipitator of mortality and contributes to a worsening of underlying comorbidities. Casserly B in their studies stated that in normotensive patients with sepsis, a lactate concentration more than 4 mmol/L was found to be independently correlated with higher mortality and therefore needs urgent recognition and proper resuscitation. [Casserly B] However, Tang Y et al stated that patients with septic shock with intermediate concentrations of lactate (2–4 mmol/L) have poorer prognosis than those with normal lactate concentration. Moreover, in the severity score, lactate weighted scoring system discriminated mortality significantly than others such as sequential organ failure assessment score. [Tang Y] According to Singer M et al the Sepsis-3 task force recommended that the monitoring of lactate should not be used as a guide to evaluate patient's therapeutic response or should not be used as an indicator of illness

severity. They recognized that serum lactate measurements are commonly, but not universally, available, especially in developing countries. [Singer M] Lactate weighted scoring system discriminate mortality significantly than others such as SOFA score and APACHE II among the severity score. Early diagnosis and prompt institution of antibiotic therapy form the cornerstone of sepsis management. There is an urgent need for tools to assess the severity of sepsis for early identification and prognostication of sick patients who warrant aggressive treatment and monitoring. This study is proposed to identify role of qSOFA score, serum lactate level and NLR in diagnosis of sepsis in early phase and their association with each other.

AIMS AND OBJECTIVES OF THE STUDY

PRIMARY OBJECTIVE

To evaluate the role of levels of NLR, lactate and qSOFA score as a predictor of sepsis in patients presenting to ED with suspected infection.

SECONDARY OBJECTIVE

- To evaluate levels of NLR, lactate and qSOFA score in predicting mortality in sepsis patients.
- To determine cut off levels for NLR and lactate values among patients with sepsis related mortality.
- To compare NLR and lactate levels with qSOFA and qSOFA alone in early prediction of sepsis in patients presented to ED with suspected infection.

MATERIALS AND METHODS

Study site:

The study was conducted in patients presenting with clinical symptoms and signs of sepsis as per Sepsis – 3 definitions, admitted to ED of BLDE (DU) Shri BM. Patil Medical College Hospital and Research Centre, Vijayapura, for the duration of November 2021 to September 2022.

Study design:

It was a single center prospective observational study.

Study population:

347 adult (≥18 years old) medical patients admitted for more than 24 hours with the clinical diagnosis of severe sepsis/septic shock as per Sepsis -3 definition at the time of admission and fulfilling all inclusion criteria were included in the study.

Sample size: Sample size was calculated by using the formula for observational studies.

$$SS = (Za)^2 PQ$$
, where

 D^2

Za = Z alpha, taken as 1.96 with 95% confidence interval

P = prevalence of disease severity in population which is considered to be 25% based on previous studies

Q (100-P) = the difference of P value from 100

D = precision of estimate, calculated as 20% of P value, since P value for this study is 25, hence value for D is 5.

After the calculation based on the above-mentioned formula, we require 300 cases to

be enrolled for this study.

Inclusion Criteria:

- All patients of age more than 18 years presenting with suspected infection to the Emergency Department.
- 2. All adult patients willing to provide informed consent for recruitment in the study.
- Documented source of infection anywhere, either clinically or by laboratory/radiological investigation.

Exclusion Criteria:

- 1. Pregnancy
- 2. Patients on immunosuppressive drugs or chemotherapy.
- 3. Patients with neuro-psychiatric illness.
- 4. Patients already on antibiotic therapy.
- 5. Medical history of hematological disorders such as leukemia, myelodysplastic syndrome, neoplastic metastases to the marrow etc.
- 6. Chronically immunosuppressed (defined as immunosuppression for solid organ transplantation, post-splenectomy, receiving ≥ 10 mg/d prednisolone or equivalent for ≥ 30 days, treatment with other immunosuppressive agents, or neutropenia [neutrophils $\leq 1.0 \times 10^9/L$]

METHODOLOGY

We recruited patients admitted to the ED according to our Institutional protocol for severe sepsis and septic shock resuscitation, prepared on the basis of Sepsis -3guidelines. Clinical examination of all recruited patients was done and vitals were recorded. Careful external examination for presence of any kind of localized lesions responsible for sepsis was done. qSOFA scoring was performed. All the samples for investigation were collected within 1 hour of patient admission and transported to the respective laboratory as per protocol. Peripheral venous blood was drawn in EDTA vacutainer under aseptic condition for Complete blood count. Hemogram was performed by fully automated 5-part hematology analyzer (Model XN1000, Sysmex, Japan). Peripheral arterial blood was drawn in a heparinized syringe under aseptic condition for Arterial blood gas (ABG) and lactate level analysis performed by fully automated ABG analyzer (Model ABL 80 FLEX, Radiometer, Japan). Blood or other body fluid or focal lesion swabs if any were collected for microbiological investigation -culture and sensitivity. Patients were sub grouped clinically into severe sepsis and septic shock based on GCS status, SBP level and serum lactate level. First of all, patients were stabilized according to ABCD management guidelines followed by which fluid resuscitation initiated with administering crystalloids at the rate of 20-30ml/kg and empirical antibiotics. Other supportive measures were taken immediately as per the department treatment protocol. All invasive procedures were performed as per requirement and lines were secured. Goal-directed therapy was applied to patients with severe sepsis associated with arterial lactate levels at least 3.0 mmol/L or those who remained hypotensive (SBP < 90 mmHg or MAP < 65 mmHg) despite fluid

resuscitation with administration of vasopressor agents, sodium bicarbonates etc. The following therapeutic goals were targeted during the first 6 hrs. of resuscitation: SBP \geq 90 mm Hg, MAP at least 65 mmHg, improvement in qSOFA score, decrease in temperature, central venous oxygen saturation (ScvO₂) at least 70%, and diuresis at least 0.5 mL/kg/h.

The following data were collected and recorded: demographic characteristics, admission diagnosis, quick Sepsis-related Organ Failure Assessment (SOFA) score, site of infection, hemodynamic and chemical parameters, administered treatments (fluids, vasopressors, steroids, and antibiotics) during the first 24 hrs. of ED admission, clinical improvement in vitals, progression or regression in organ function status and mortality at day 1.

STATISTICAL ANALYSIS

All the data were collected by using a pretested proforma meeting the objectives of the study. Detailed history, physical examination and necessary investigations had undertaken. The purpose of the study was explained to the patient in their own language and informed consent obtained. All the clinical and laboratory data were gathered and entered in Microsoft Excel sheet.

Categorical variables were expressed as absolute numbers and in relative frequencies (%) whereas numerical variables were presented as Mean \pm SD and continuous variables as Mean with confidence interval at 95% level (CI 95%).

Binary variables were compared with chi-square test or with Fisher exact test when appropriate. Comparison of numerical variables between groups will be found using unpaired t-test/ Anova test.


A receiver-operating characteristic (ROC) curve was constructed to assess the best blood lactate level and NLR cutoff related to mortality at day 1. Subsequently, patients were dichotomized according to the lactate and NLR cutoff separately chosen by ROC curve analysis. We calculated sensitivity and specificity value for the cutoff values of Lactate and NLR. We also constructed ROC curves to test the ability of initial lactate levels, NLR and qSOFA score to predict mortality at day 1 in the subgroup of patients of ED admission.

RESULTS

347 patients admitted to ED who fulfilled the criteria for severe sepsis or septic shock based on Sepsis-3 are enrolled and prospectively evaluated in the study period from NOV 2021 to SEP 2022. 47 patients are excluded from the study because of different reasons like death within 1 hour of admission (7), presence of hematological diseases, malignancies, immunological disorders, on glucocorticoid therapy for more than five days (27) and incomplete history and data due to loss to follow up (13). [Figure 1]

FLOW DIAGRAM OF PATIENT RECRUITMENT

FIGURE 1.



RESULT

Total 300 patients were included in the study and data were gathered and analyzed. We analyzed the frequency of categorical variables like age, gender, survivors, nonsurvivors, qSOFA score with disease outcome, culture positive or negative, patients with sepsis with or without vasopressors etc. in Mean \pm SD and percentage. Continuous variables we selected in our study were lactate and NLR levels in microbiologically confirmed cases of sepsis, their sensitivity and specificity in early diagnosis, finding a cut off value for these variables in relation with clinical outcome in sepsis and correlation of them with qSOFA score in combination and alone. The Mean age of study population is 49.54 years (range19 - 98 years) with most of them are \geq 39 years. The gender distribution is as 186 males (62.00%) and 114 females (38.00%). This study shows higher prevalence of sepsis among middle aged male patients than younger or elderly population. We sub grouped patients into four groups based on the age range with difference of twenty years in first three groups and fourth one with patients having age > 79 years. We observed that there is no significant difference between age distribution among males and females in group one i.e. early age with sepsis but group two, three and four shows males are affected more with sepsis in comparison to females. [Table 1, Figure 2&3]

TABLE 1: DISTRIBUTION OF CASES BY AGE AND GENDER

Age Range (years)	Male (%)	Female (%)	Total cases	Percentage
19 – 38	48 (25.81%)	47 (41.23%)	95	31.67%
39 – 58	71 (38.17%)	25 (21.93%)	96	32.00%
59 – 78	59 (31.72%)	32 (28.07%)	91	30.33%
>79	8 (04.30%)	10 (08.77%)	18	06.00%
Total	186 (62.00%)	114 (38.00%)	300	100.00%

FIGURE 2: DISTRIBUTION OF CASES BY AGE AND GENDER





FIGURE 3: OVERALL GENDER DISTRIBUTION OF CASES



The usual patient stabilization and observation time in ED in our Institute is 12 to 24 hours after which patients are shifted to respective departments. Patients are managed according to Surviving Sepsis Guideline. We assessed clinical condition and survival of patients at 24 hours post admission. Patients are subdivided into two groups, Group I i.e., Survivor (S) and Group II i.e., Nonsurvivor (NS) based upon their survival after 24 hours of admission. The age and gender distribution among both groups show high prevalence in middle age group i.e., 39 to 58 years with male predominance (Male: Female ratio 10:1). Mean age in Survivor and Non-survivor group is 49.18 ± 18.05 years (CI 95% 46.99 - 51.37) and 52.11 ± 19.13 years (CI 95% 45.73 - 58.49) observed in this study which indicates favorable survival outcome among younger age than extremes of age. [Table 2, Figure 4&5]

TABLE 2. DISTRIBUTION OF AGE AND GENDER AMONG SURVIVOR AND NONSURVIVOR GROUPS

Va	Variables			Group II (NS)		
Number of	Number of patients: N (%)			37 (12.33%)		
	19 – 38 years	M	43 (16.35%)	5 (13.51%)		
	yours	F	42 (15.95%)	5 (13.51%)		
	39 – 58 years	M	63 (23.95%)	10 (27.03%)		
Age group: N (%)	years	F	25 (9.51%)	1 (2.70%)		
	59 – 78 years	M	50 (19.01%)	7 (18.92%)		
	years	F	30 (11.41%)	3 (8.11%)		
	> 79 years	M	6 (2.28%)	3 (8.11%)		
		F	4 (1.52%)	3 (8.11%)		

FIGURE 4: DIAGRAMMATIC REPRESENTATION OF AGE DISTRIBUTION BETWEEN SURVIVOR AND NON-SURVIVOR GROUPS





FIGURE 5: DIAGRAMMATIC REPRESENTATION OF GENDER DISTRIBUTION BETWEEN SURVIVOR AND NON-SURVIVOR GROUPS



Patients with qSOFA score of 2 and 3 are selected for recruitment in the study and compared among (S) and (NS) groups. Patients with lower score of 2 had better survival than score 3. Among patients with score of 3, 61.05% are in survivor group in comparison to 38.95% in non-survivor group. qSOFA with score 2 shows fair agreement among Survivor group with male predominance whereas qSOFA score 3 shows no statistical significance among survivors and nonsurvivors when categorical variable, gender is compared with chi-square test. The chi-square statistic was 1.31 without Yates correction and 0.86 with Yates correction. All the patients irrespective of Survivor or Nonsurvivor group had received fluid resuscitation for underlying hypotension and observed for correction of SBP > 90 mm Hg or MAP > 65 mm Hg within first hour of admission. Those patients who failed to reach the targeted SBP and or MAP are further managed with vasopressor. Out of 300 patients, 164 (54.67%) required vasopressor in addition to fluid therapy for stabilization of SBP and/or MAP and rest 136 (45.33%) were responded well to fluid therapy and other supportive treatment. Correlation of qSOFA score with gender in both (S) and (NS) groups shows male predominance. Vasopressive agents are administered to all the patients having qSOFA score of 3 (survivors and nonsurvivors) and non-responders to fluid therapy within 10 minutes of administration among those with qSOFA score 2. 77.47% patients survive after administration of vasopressive agents (127/164) with qSOFA score 2 and 3, P < 0.003. [Table 3, Figure 6&7]

Gender	Patients on vasopressor with qSOFA score 2	Patients on vasopressor with qSOFA score 3
Male: n (%)	66 (73.33%)	49 (66.22%)
Female: n (%)	24 (26.67%)	25 (33.78%)
Total: n (%)	90 (100%)	74 (100%)

FIGURE 6. HISTOGRAM SHOWING THE DIFFERENCE IN qSOFA SCORE AT ADMISSION BETWEEN SURVIVORS (S) AND NON-SURVIVORS (NS)





FIGURE 7. HISTOGRAM SHOWING GENDER DISTRIBUTION AMONG qSOFA CASES REQUIRING VASOPRESSOR



Hemogram of patients shows leucocytosis with neutrophilia predominantly followed by lymphopenia and leucopenia. Neutrophilia shows left shift upto band forms (bandemia > 10%), presence of cytoplasmic azurophilic granules, toxic granules and vacuoles and occasionally apoptotic cells. The average distribution of total leucocyte count (TLC), absolute neutrophil count (ANC) and absolute lymphocyte count (ALC) in this study was 770 to 80480, Mean 16411.29 ± 10175.6 (CI 95% 15255.16-17567.43), 97.23 to 77421.76, Mean 14043.3 \pm 9563.32 (CI 95% 12956.71-15129.85) and 11.59 to 31297.41, Mean 1715.45 \pm 2790.89 (CI 95% 1398.35 - 2032.54) respectively. The hemogram analysis reveals higher TLC (35.14%), ANC (59.45%) and NLR (64.86%) and low ALC (67.57%) among males of non-survivor group in comparison to those in survivor group. Among survivor group, males have higher ANC (49.05%) and NLR (56.65%) and low ALC (60.08%) than females. The mean value for NLR and lactate in this study is reported as 15.47 ± 15.07 (CI 95% 13.76 -17.19) and 3.27 ± 3.02 (CI 95% 2.93 – 3.62) respectively. The maximum value observed for NLR and lactate was 87.9 and 27 respectively in this study. [Table 4 &5]

TABLE 4. DISTRIBUTION OF HEMOGRAM AMONG SURVIVOR AND NON – SURVIVOR GROUPS

Subgroup	Sex	TLC (pe	r μl)	ANC (pe	er µl)	ALC (pe	er μl)	NLR	
		>15000	< 15000	> 7000	< 7000	> 4000	< 4000	> 3	< 3
Nonsurvivor (NS)	M	35.14%	32.43%	59.45%	8.11%	00.00%	67.57%	64.86%	2.71%
(143)	F	21.62%	10.81%	27.03%	5.41%	5.41%	27.02%	24.33%	8.10%
Survivor (S)	M	24.72%	36.88%	49.05%	12.55%	1.52%	60.08%	56.65%	4.94%
	F	18.63%	19.77%	28.90%	9.50%	3.80%	34.60%	31.94%	6.46%

Table 5: COMPARISON OF DEMOGRAPHIC & CLINICAL DATA BETWEEN SURVIVORS AND NON-SURVIVORS

Varia	ıbles	Survivo	Non survivors (n=37/300)			
		Sex	N (%)	N (%)		
Age N (%)	19 – 38 years	M	43 (16.35%)	5 (13.51%)		
		F	42 (15.95%)	5 (13.51%)		
	39 – 58 years	M	63 (23.95%)	10 (27.03%)		
		F	25 (9.51%)	1 (2.70%)		
	59 – 78 years	M	50 (19.01%)	7 (18.92%)		
		F	30 (11.41%)	3 (8.11%)		
	> 79 years	M	6 (2.28%)	3 (8.11%)		
		F	4 (1.52%)	3 (8.11%)		
qSOFA Score	2	M	125 (47.53%)	00 (00.00%)		
		F	80 (30.42%)	00 (00.00%)		
	3	M	34 (12.93%)	26 (70.27%)		
		F	24 (9.12%)	11 (29.73%)		
TLC	< 15000	M	95 (36.12%)	13 (35.14%)		
		F	53 (20.15%)	3 (8.11%)		
	> 15000	M	63 (23.95%)	13 (35.14%)		
		F	52 (19.78%)	8 (21.61%)		
PMN	< 7000	M	12 (4.56%)	2 (5.40%)		
		F	16 (6.08%)	00 (00.00%)		
	> 7000	M	143 (54.37%)	25 (67.57%)		
		F	92 (34.99%)	10 (27.03%)		
LYMPHO	< 4000	M	158 (60.08%)	25 (67.57%)		
		F	91 (34.60%)	10 (27.02%)		
	> 4000	M	4 (1.52%)	00 (00.00%)		


		F	10 (3.80%)	2 (5.41%)
NLR	< 3	M	13(4.94%)	1 (2.71%)
		F	17 (6.46%)	3 (8.10%)
	> 3	M	149 (56.65%)	24 (64.86%)
		F	84 (31.94%)	9 (24.33%)
LACTATE	< 4	M	139 (52.85%)	0 (00.00%)
		F	88 (33.46%)	0 (00.00%)
	> 4	M	22 (8.37%)	26 (70.27%)
		F	14 (5.32%)	11 (29.73%)

The site of infection is also analyzed in this study. Out of 300 cases only 106 (35.33%) are culture positive for pathogenic organisms. Systemic and cutaneous and soft tissue sites of infection show higher frequency among both the groups (S & NS). The gender distribution shows male predominance (69.81%) in systemic and cutaneous and soft tissue infection among both the groups (S & NS). This may happen due to availability of incomplete history regarding previous intake of antibiotics by patients for their underlying illness about which they are not aware at the time of providing history about drug intake. [Table 6, Figure 8]

Table 6: DISTRIBUTION OF CASES BY SITE OF SEPSIS

Site of sepsis	Frequency distribution	Survivor grou	ıp: N (%)	Non survivor group: N (%)		
	among patients:	M		M	F	
	N (%)					
Respiratory	13(12.26%)	7(6.61%)	5(4.72%)	1(0.94%)	0(00.00%)	
Urogenital Tract	26(24.53%)	11(10.38%)	10(9.43%)	3(2.83%)	2(1.88%)	
Skin And Soft Tissue	29(27.36%)	20(18.88%)	8(7.55%)	1(0.94%)	0(00.00%)	
Systemic	38(35.85%)	25(23.58%)	8(7.55%)	4(3.77%)	1(0.94%)	
Total	106	63(59.45%)	31(29.25%)	9(8.48%)	3(2.82%)	


FIGURE8. HISTOGRAM SHOWING FREQUENCY DISTRIBUTION OF SITES OF INFECTION AMONG SURVIVOR AND NON-SURVIVOR GROUPS



A Receiver-operating characteristic (ROC) curve was constructed to assess the best blood lactate level and NLR cutoff related to mortality at day 1. Subsequently, patients were dichotomized according to the lactate and NLR cutoff separately chosen by ROC curve analysis. We calculated sensitivity and specificity value for the cutoff values of Lactate and NLR. We also constructed ROC curves to test the ability of initial lactate levels, NLR and qSOFA score to predict mortality at day 1 in the subgroup of patients of ED admission. Highest sensitivity (50.26) and specificity (54.21) observed for serum lactate level at 2.5 mmol/L value hence cut off point was rounded off to 3 in this study for ease of calculation. NLR level shows poor sensitivity but higher specificity with value 45.2. Hence, we difficult to derive a cut off value for NLR value in this study.


Receiver operating characteristic curve analysis was performed to assess the diagnostic accuracy for predicting disease outcome at day 1 and the area under the curve (AUC) was calculated. The area under curve (AUC) for NLR shows good predictive value with accuracy for diagnosis of sepsis as an independent marker. [Figure 9]

FIGURE 9. ROC CURVE FOR NLR AS A DIAGNOSTIC MARKER FOR EARLY SEPSIS



The ROC curve for qSOFA score, NLR and serum lactate shows poor sensitivity but good specificity. The combined use of qSOFA score, serum lactate and NLR to detect sepsis at the earliest is analyzed by using ROC curve. [Figure 10]

FIGURE 10. ROC CURVE OF qSOFA, NLR AND LACTATE AS
DIAGNOSTIC MARKER FOR EARLY SEPSIS



Correlation between qSOFA score, serum lactate level and NLR with culture reports was analyzed by using paired Student T – Test that shows significant association between them (p < 0.001).

Level of TLC and serum lactate as predictor of disease outcome (S & NS groups) was analyzed by logistic regression that shows significant association with disease outcome with Odds Ratio 1.000 and 1.989 (p =0.032, p<0.001) respectively. NLR was found to be no longer effective in predicting disease outcome, OR 0.997 (p=0.841). Correlation matrix for qSOFA score with serum lactate level (p<0.001) and with NLR (p=0.009) was significant however NLR with serum lactate was found to be non-significant.

We did univariate analysis and compared qSOFA score, NLR and lactate levels between survivors and non-survivors. Outcome shows significant association of qSOFA score (p<0.001) and serum lactate levels however NLR is a poor indicator for outcome (p=0.773). All these three variables are found to be independent predictor of disease diagnosis and outcome as well.

This study had analyzed demographic data, patient outcome, role of three mostly used markers in sepsis –qSOFA score, serum lactate level and NLR individually and in combination to discover their utility as a diagnostic tool for sepsis in early phase. The result shows good correlation of qSOFA score and serum lactate levels in early diagnosis of sepsis but role of NLR is questionable.

DISCUSSION

Early phase of sepsis needs easy clinical parameters for patient assessment without any assistance and rapid bedside investigations that could assess biochemical and hematological parameters accurately. Several studies had reported qSOFA as a good independent predictor of sepsis and is easy to perform. [Singer M, Marik PE,] We observed that the incidence of sepsis is higher among middle aged group males and females in our study which is in coherence with Daga MK study. [Daga MK] Kaushik R et al also reported mean age of 30 years among patients with sepsis in their study which is a decade earlier than in our study (49.54 years). [Kaushik R] The median age (50 years) in this study is varied by two decades earlier in comparison to western world. [Filho RR, Chicco D] However this variation in age prevalence is may be due to drastic change in life style, especially dietary habits, in past two decades among Indian population and small sample size in comparison to other studies. The study shows mean age of 52 years among nonsurvivors suggesting risk of mortality increases with senescence. The sepsis related mortality rate was 12.33 % and is correlated well with the studies of Singer M et al. [Singer M] In the present study, the primary outcome, i.e., mortality at day 1, was 12.33% which is similar to be reported in study of Filho R R et al (12.77%). [Filho RR] Frequency of site-specific sepsis was also analyzed in this study and we observed that bacteremia was the most common site of sepsis (35.85%) meant by presence of pathogen within blood, followed by cutaneous (27.36%) and urogenital infections

(24.53%). Filho RR et al reported respiratory tract infection (50.6%) as most common

site followed by urinary tract infection (20.3%) in sepsis patients in their study. This variation may be due to epidemiological and demographic factors.

The primary outcome of this study was to describe role of three most commonly used markers of sepsis independently and in combination.

Most of the studies compared several scores as screening, diagnostic and prognostic tool for sepsis like APACHE II, SOFA score, qSOFA score etc and found that qSOFA score is a good predictor of sepsis in prognostic aspects and with mortality also. The qSOFA score in this study shows poor outcome with score of 3 in comparison to score of 2. Shahsavarinia K et al observed 66.3% sensitivity and 60.6% specificity for qSOFA in detection of sepsis and recommended that qSOFA as a good prognostic marker but not for diagnosis. [Shahsavarinia K] Rhodes A et al had clearly recommended that though qSOFA is a good predictor of mortality, it cannot be used singly for screening and diagnosis of sepsis. This score was not included in the most recent Surviving Sepsis Campaign guidelines 2017 to screen or diagnose sepsis. [Rhodes A] Several other researches had also compared effectiveness of qSOFA with SOFA and found that qSOFA could predict disease outcome more significantly and since it is very easy to perform even in patients with altered mental status and not included any laboratory marker, most of them favor to use it. We correlated qSOFA score with culture report for diagnostic confirmation and found significant relation between the two (p < 0.001).

Serum lactate level measurement at the time of ED admission is very important and valuable marker as baseline level it can be used for further monitoring and prognosis of patients. In addition to that since it's a marker of tissue hypoxia and hypoperfusion

the level of this marker will help in definite therapy of hypotension at the earliest with better choice of regimen. The median for serum lactate level among patients with sepsis at the time of admission in ED was 2.4 which is well correlated with that found in study of Filho RR. We observed that serum lactate level at 2.5 mmol/L have highest sensitivity and specificity in diagnosing the disease itself and in prognosis of disease associated mortality. This finding is in coherence with that reported by Filho R R et al. They observed that initial lactate levels above 2.5 mmol/L had a mortality rate 3.2 times higher than patients with initial normal lactate level. [Filho RR] Thus we recommend use of a cut off value of 3mmol/L (rounded off) to be considered for diagnostic purpose. However, serum lactate level is influenced by several factors hence its independent use as screening and diagnostic tool requires further large-scale study with inclusion of all possible factors determining serum lactate level.

Complexity of numerical and morphological presentation of hemogram in sepsis make its interpretation challenging as there is involvement of peripheral and central hematological cellular pool well regulated by various chemical mediators. Since multiple factors are activated simultaneously in sepsis like external or internal pathogens, acute inflammatory response releasing chemical mediators at a higher rate and hypoxia induced diffuse tissue injury. Hence, we found TLC and ANC as a good predictor of disease outcome in sepsis but are poorly correlated with culture reports. This may happen due to heterogenous response of myeloid cells towards pathogen in population.

TLC was well correlated with diagnosis of sepsis in early phase with mean of 16.41 \pm 10.17(95% CI – 11.56) in this study. Similar values were reported by Liu X et al

(mean 16.07 ± 6.63). [Liu X et al] Both leucocytosis and leucopenia were associated with poor prognosis. The differential count of white blood cells shows markedly high ANC and markedly low ALC. Thus, we found higher value for NLR among cases having TLC within normal range. NLR plays an important role in disease prognosis in such situation. This may be due to various underlying factors. Most important among them are early stage of effective bone marrow suppression by underlying disease with superadded sepsis mediated increase in chemical mediators (IL-6), medication, fluid imbalance etc. TLC, ANC, ALC and NLR were studied individually and in combination, as diagnostic marker for sepsis by several researchers. Kaushik R et al found NLR at a value of ≥ 3.3 with higher sensitivity and specificity (87.5% & 90%) respectively) and recommended it as a diagnostic marker in early phase of sepsis. Our study shows poor outcome with NLR of > 10 among patients in early phase of sepsis. ALC shows lymphopenia of moderate to severe degree in sepsis patients at early phase which correlates well with the study of Kaushik R. et al and Jilma et al. Jilma et al observed persistently high ANC among patients with sepsis and concluded that these patients have very poor outcome due to persistent lymphocytopenia. [KaushikR, Jilma] The median value for NLR was 10.58 in this study similar to be reported by Ahmed M.A.M.S. et al (median NLR value 8.6). They concluded that NLR at day 1 of admission is a good prognostic marker for mortality but haven't commented upon its use as diagnostic tool. NLR with culture reports show positive correlation (p<0.001) similar to the study of Liu X et al who reported higher NLR in positive blood culture cases (p=0.000). [Liu X]

qSOFA score (2 & 3), hyperlactatemia (\geq 3 mmol/L) and NLR (>3) shows significant

role in prediction of disease severity and mortality at day 1 of ED admission when studied individually. We observed correlation between individual and combined use of these markers in diagnosis and prognosis of sepsis.

Combined use of qSOFA score and serum lactate is studied vigorously till now and proven prognostic markers independently and in combination both among sepsis patients. There was positive correlation between qSOFA and serum lactate level with culture reports and disease outcome in present study and is in coherence with the study of Filho RR et al and Daga MK. Daga MK termed LqSOFA when it is used in combination with lactate level of > 2 mmol/L. They also recommended these markers as prognostic tool. [Filho RR, Daga MK] qSOFA and NLR shows positive correlation to predict disease outcome (p=0.009) similar to reported by Li Y et al in their study. They concluded significantly higher sensitivity and specificity of qSOFA and NLR as a prognostic marker for prediction of mortality when used in combination. Though they haven't studied diagnostic role of these two markers. [Li Y]

The combined use of qSOFA score with serum lactate level and NLR for diagnosis of sepsis in early phase is noninferior than their individual use. This study observed that

sepsis in early phase is noninferior than their individual use. This study observed that though all these three markers are very good predictor of mortality at day 1 of ED admission they are not showing superior effect in comparison to their individual utilization. However, we recommend that multiple factors are regulating the clinical state of patients presenting in ED, further study at large scale will be needed with inclusion of these possible factors to understand the effectiveness of utility of these markers in sepsis.

STRENGTHS & LIMITATIONS

This study had a prospective design. All patients were managed under similar settings with uniform institutional management protocol based on surviving sepsis guidelines. The patients were first categorized into severe sepsis or septic shock followed by immediate initiation of sepsis bundle of management. We attempted to follow all the instructions according to Institutional guidelines and stick to patient selection criteria as per study design protocol. The clinical outcome in this study shows satisfactory results that may be due to early and rapid clinical assessment and diagnosis which is further supported by easy to perform and early to avail serum lactate and NLR values. However, the present study is not exempted from limitations. Since the markers we selected are more common than the other one, a large-scale study including thousands of populations is needed to validate the results we observed. We are limited in time period for study population recruitment (12 months) hence unable to recruit patients on a large scale. We observed poor correlation of these markers with culture reports. This may have limitations in difficulty to obtain proper history as patients came in critically ill condition thus not in a state of providing detailed history regarding previous drug intake. Since this was a single Centre study conducted in a tertiary care institution, results may not be generalized to the entire population. Hemogram shows extremes of values that are not well correlated with lactate levels, qSOFA and culture reports. This may happen as hematological response is time dependent and respond heterogeneously with multifactorial events occurring simultaneously among patients with sepsis. In addition to this there are several limitations related to logistics and at technical grounds were affected the result of our study.

CONCLUSIONS

In this prospective observational study, 300 patients admitted to ED with symptoms and signs suggestive of sepsis, qSOFA score, serum lactate level and NLR were assessed within two hours of admission with the aim to utilize them as early predictor of sepsis. We conclude that these markers had significant role in prognosis of disease outcome in the form of day1 mortality independently and in combination but to diagnose sepsis in early phase when culture reports are not available, they show heterogenous behavior. qSOFA with serum hyperlactatemia (> 3 mmol/L) is a good predictor in diagnosing early phase of sepsis without waiting for culture reports but NLR is a poor predictor for the same. Hence, we recommend that further research is needed to find a new gold standard to replace culture report so that we could utilize the golden period within time in sepsis patients to save their life.

BIBLIOGRAPHY

- Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801-10.
- 2. Lever A, Mackenzie I. Sepsis: Definition, epidemiology, and diagnosis. BMJ 2007;335:879-83.
- 3. Rich'e F, Gayat E, Barth'el'emy R, Le Dorze M, Mat'eo J, Payen D.Reversal of neutrophil-to-lymphocyte count ratio in early versus late death from septic shock. Critical Care.2015;19: 439.
- 4. Faix JD.Biomarkers of sepsis. Crit Rev Clin Lab Sci. 2013;50(1):23-36.
- Williams JM, Greenslade JH, McKenzie JV, Chu K, Brown AFT, Lipman J. Systemic Inflammatory Response Syndrome, Quick Sequential Organ Function Assessment, and Organ Dysfunction: Insights From a Prospective Database of ED Patients With Infection. Chest. 2017 Mar;151(3):586-596.
- 6. Farkas J.Neutrophil-Lymphocyte Ratio (NLR): Free upgrade to your WBC. PulmCrit .2019;10:1-14.
- 7. Suetrong B, Walley KR. Lactic acidosis in sepsis: it's not all anaerobic: implications for diagnosis and management. Chest 2016;149:252-61.
- 8. Kraut JA, Madias NE. Lactic acidosis. N Engl J Med 2014;371:2309-19.
- 9. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al. Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med.200;345(19):1368-77.
- 10. Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, Willemsen SP, Bakker J; LACTATE study group. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010;182(6):752-61.

- 11. Biron BM, Ayala A, Lomas-Neira JL. Biomarkers for sepsis: Wkhat is and what might be?.Biomarker Insights.2015;10(Suppl 4):7-17.
- 12. Gyawali B, Ramakrishna K, Dhamoon S. Sepsis:The evolution in definition, pathophysiology and management. SAGE Open Med.2019;7:1-13.
- 13. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference:

 Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med.1992;20:864-74.
- 14. Marik PE, Taeb AM. SIRS, qSOFA and new sepsis definition. J Thorac Dis. 2017;9(4):943-45.
- 15. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-55.
- 16. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
- 17. Zahorec R. Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5-14.
- 18. Jiang J, Liu R, Yu X, Yang R, Xu H, Mao Z et al. The neutrophil-lymphocyte count ratio as a diagnostic marker for bacteraemia: A systematic review and meta-analysis. Am J Emerg Med. 2019;37(8):1482-89.
- 19. Ljungström L, Pernestig A, Jacobsson G, Andersson R, Usener B, Tilevik D. Diagnostic accuracy

- of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis. PLoS One. 2017;12(7):e0181704.
- 20. Salciccioli JD, Marshall DC, Pimentel MA, Santos MD, Pollard T, Celi LA et al. The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study. Crit Care. 2015;19(1):13.
- 21. Rodriguez RM, Greenwood JC, Nuckton TJ. Comparison of qSOFA with current emergency department tools for screening of patients with sepsis for critical illness. Emerg Med J. 2018;35(6):350-356.
- 22. Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA score for In-hospital mortality among adults with suspected infection admitted to the Intensive Care Unit. JAMA. 2017;317:290-300.
- 23. Peirovifar A, Eydi M, Mirinejhad MM, Mahmoodpoor A, Mohammadi A, Golzari SE.

 Comparison of postoperative complication between Laryngeal Mask Airway and endotracheal tube during low-flow anesthesia with controlled ventilation. Pak J Med Sci. 2013;29(2):601-05.
- 24. Jeppesen JB, Mortensen C, Bendtsen F, Moller S. Lactate metabolism in chronic liver disease. Scand J Clin Lab Invest. 2013;73(4):293-9.
- 25. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J. Surviving Sepsis Campaign. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010;38(2):367-74.
- 26. Lee SM, Kim SE, Kim EB, Jeong HJ, Son YK, An WS. Lactate Clearance and Vasopressor Seem to Be Predictors for Mortality in Severe Sepsis Patients with Lactic Acidosis Supplementing Sodium Bicarbonate: A Retrospective Analysis. PLoS One. 2015;10(12):e0145181.
- 27. Rady MY, Rivers EP, Nowak RM. Resuscitation of the critically ill in the ED: responses of blood

- pressure, heart rate, shock index, central venous oxygen saturation, and lactate. Am J Emerg Med. 1996; 14 2:218–25.
- 28. Liu X, Shen Y, Wang H, Ge Q, Fei A, Pan S. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Sepsis: A Prospective Observational Study. Mediators Inflamm. 2016;2016:8191254.
- 29. Younan D, Richman J, Zaky A, Pittet JF. An Increasing Neutrophil-to-Lymphocyte Ratio Trajectory Predicts Organ Failure in Critically-Ill Male Trauma Patients. An Exploratory Study. Healthcare .2019; 7(42): 1-8.
- 30. Soulaiman SE, Dopa D, Raad AT, Hasan W, Ibrahim N, Hasan A et al. Cohort retrospective study: the neutrophil to lymphocyte ratio as an independent predictor of outcomes at the presentation of the multi-trauma patient. Int J Em Med. 2020;13:5.
- 31. Connor H, Woods HF. Quantitative aspects of L(+)- lactate metabolism in human beings. Ciba Found Symp.1982;87:214-34.
- 32. Foucher CD, Tubben RE. Lactic Acidosis. StatPearls. Treasure Island (FL)2017.
- 33. Levy B. Lactate and shock state: the metabolic view. Curr Opin Crit Care. 2006;12:315-21.
- 34. Garcia-Alvarez M, Marik P, Bellomo R. Sepsis-associated hyperlactatemia. Crit Care. 2014;18:503.
- 35. Sun S, Li H, Chen J, Qian Q. Lactic Acid: No Longer an Inert and End-Product of Glycolysis. Physiology (Bethesda).2017;32(6):453-63.
- 36. Nasi A, Fekete T, Krishnamurthy A, Snowden S, Rajnavölgyi E, Catrina AI. Dendritic cell reprogramming by endogenously produced lactic acid. J Immunol.2013;191(6):3090-9.
- 37. Errea A, Cayet D, Marchetti P, Tang C, Kluza J, Offermanns S. Lactate Inhibits the Pro-

- Inflammatory Response and Metabolic Reprogramming in Murine Macrophages in a GPR81-Independent Manner. PLoS One.2016;11(11):e0163694.
- 38. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013;191(3):1486-95.
- 39. Mahnensmith RL, Aronson PS. The plasma membrane sodium-hydrogen exchanger and its role in physiological and pathophysiological processes. Circ Res.1985;56:773-88.
- 40. Malo ME, Fliegel L. Physiological role and regulation of the Na+/H+ exchanger. Can J Physiol Pharmacol.2006;84:1081-95.
- 41. Regli L, Anderson RE, Meyer FB. Effects of intermittent reperfusion on brain pHi, rCBF, and NADH during rabbit focal cerebral ischemia. Stroke.1995;26:1444-51;discussion 51-2.
- 42. Sikes PJ, Zhao P, Maass DL, White J, Horton JW. Sodium/hydrogen exchange activity in sepsis and in sepsis complicated by previous injury: 31P and 23Na NMR study. Crit Care Med. 2005 Mar;33(3):605-15.
- 43. Wu D, Kraut JA. Potential role of NHE1 (sodium hydrogen exchanger 1) in the cellular dysfunction of lactic acidosis: implications for treatment. Am J Kidney Dis. 2011;57:781-7.
- 44. Herbertson MJ, Werner HA, Russell JA, Iversen K, Walley KR. Myocardial oxygen extraction ratio is decreased during endotoxemia in pigs. J Appl Physiol (1985). 1995;79(2):479-86.
- 45. Levraut J, Ciebiera JP, Chave S, Rabary O, Jambou P, Carles M et al. Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1021-6.
- 46. Casserly B, Phillips GS, Schorr C, Dellinger RP, Townsend SR, Osborn TM et al. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis

- Campaign database. Crit Care Med. 2015;43(3):567-73.
- 47. Tang Y, Choi J, Kim D, Tudtud-Hans L, Li J, Michel A et al. Clinical predictors of adverse outcome in severe sepsis patients with lactate 2-4 mM admitted to the hospital. QJM. 2015;108(4):279-87.
- 48. Daga MK, Rohatgi I, Mishra R, KumarN, Mawari G, Mishra TK et al. Lactate enhanced-quick Sequential Organ Failure Assessment 2 (LqSOFA2): A new score for bedside prognostication of patients with sepsis. Indian J Med Res.2021;154:607-14.
- 49. Kaushik R, Gupta M, Sharma M, Jash D, Jain N, Sinha N et al. Diagnostic and Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Early and Late Phase of Sepsis. Indian J Crit Care Med. 2018;22(9):660-63.
- 50. Filho RR, Rocha LL, Corrêa TD, Pessoa CM, Colombo G, Assuncao MS. Blood Lactate Levels Cutoff and Mortality Prediction in Sepsis-Time for a Reappraisal? a Retrospective Cohort Study. Shock. 2016;46(5):480-85.
- 51. Chicco D, Jurman G. Survival prediction of patients with sepsis from age, sex, and septic episode number alone. Sci Rep.2020;10:17156.
- 52. Shahsavarinia K, Moharramzadeh P, Arvanagi RJ, Mahmoodpoor A. qSOFA score for prediction of sepsis outcome in emergency department. Pak J Med Sci. 2020;36(4):668-72.
- 53. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock:2016. Crit Care Med.2017;45(3):486-552.
- 54. Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit

Care Med.1999;159:857-63.


55. Li Y, Wang J, Wei B, Zhang X, Hu L, Ye X. Value of Neutrophil:Lymphocyte Ratio

Combined with Sequential Organ Failure Assessment Score in Assessing the Prognosis of

Sepsis Patients. Int J Gen Med. 2022;15:1901-08.

ANNEXURE I

ETHICAL COMMITTEE CERTIFICATE



ANNEXURE II

INFORMED CONSENT FORM

BLDE (DEEMED TO BE UNIVERSITY) SHRI B. M. PATIL MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE, VIJAYAPUR KARNATAKA-586103

TITLE OF THE PROJECT —Combined use of NLR, Lactate and qSOFA as early prediction of sepsis in patients presenting to Emergency department.

PRINCIPAL INVESTIGATOR - Dr. RAKESH KUMAR

P.G. GUIDE NAME –DR. RAVI B PATIL MS (GENERAL SURGERY)

PROFESSOR AND HOD, DEPARTMENT OF EMERGENCY MEDICINE

All aspects of this consent form are explained to the patient in the language understood by him/her.

I) INFORMED PART

- 1) **PURPOSE OF RESEARCH:** I have been informed about this study. I have also been given a free choice of participation in this study.
- 2) **PROCEDURE:** I am aware that in addition to routine care received I will be asked series of questions by the investigator. I have been asked to undergo the necessary investigations and treatment, which will help the investigator in this study.
- 3) **RISK AND DISCOMFORTS:** I understand that I may experience some pain and discomfort during the examination or during my treatment. This is mainly the result of

my condition and the procedure of this study is not expected to exaggerate these feelings that are associated with the usual course of treatment.

- **4) BENEFITS:** I understand that my participation in this study will help to patient's survival and better outcome.
- 5) CONFIDENTIALITY: I understand that the medical information produced by this study will become a part of Hospital records and will be subject to the confidentiality and privacy regulation. Information of a sensitive personal nature will not be a part of the medical records, but will be stored in the investigator's research file and identified only by code number. The code-key connecting name to numbers will be kept in a separate location. If the data are used for publication in the medical literature or for teaching purpose, no name will be used and other identifiers such as photographs and audio or videotapes will be used only with my special written permission. I understand that I may see the photographs and videotapes and hear the audiotapes before giving this permission.
- 6) REQUEST FOR MORE INFORMATION: I understand that I may ask more questions about the study at any time. Dr. RAKESH KUMAR is available to answer my questions or concerns. I understand that I will be informed of any significant new findings discovered during the course of the study, which might influence my continued participation. If during the study, or later, I wish to discuss my participation in or concerns regarding this study with a person not directly involved, I am aware that the social worker of the hospital is available to talk with me. A copy of this consent form will be given to me to keep for careful reading.

- 7) REFUSAL OR WITHDRAWAL OF PARTICIPATION: I understand that my participation is voluntary and that I may refuse to participate or may withdraw consent and discontinue participation in the study at any time without prejudice to my present or future care at this hospital. I also understand that Dr. RAKESH KUMAR may terminate my participation in the study after he has explained the reasons for doing so and has helped arrange for my continued care by my own physician or physical therapist, if this is appropriate
- 8) INJURY STATEMENT: I understand that in the unlikely event of injury to me resulting directly from my participation in this study, if such injury were reported promptly, the appropriate treatment would be available to me, but no further compensation would be provided. I understand that by my agreement to participate in this study I am not waiving any of my legal rights.

I have explained to _____ the purpose of the research, the

procedures required and the possible risks and benefit	ts to the best of my ability in
patient's own language.	
Dr. RAKESH KUMAR	Date (Investigator)

II) STUDY SUBJECT CONSENT STATEMENT:

I confirm that Dr. RAKESH KUMAR has explained to me the purpose of research, the study procedures that I will undergo, and the possible risks and discomforts as well as benefits that I may experience in my own language. I have read and I understand this consent form. Therefore, I agree to give consent to participate as a subject in this research project.

Participant / Guardian	Date
Witness to signature	Date

ANNEXURE III

BLDE (Deemed to be) UNIVERSITY, SHRI B.M. PATIL MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE, VIJAYAPURA KARNATAKA Combined use of NLR, Lactate and qSOFA as easily prediction in patients presenting to Emergency department

Name:		CASE NO:					
Age:		IP NO:					
Sex:		DOA:					
Religion:		DOD:					
Occupation:		Residence:					
Phone No:							
Presenting complaints with	duration:						
• Past history							
Treatment History:							
General Physical Examinati	ion						
Vitals							
PR:	BP:	RR:					
Temp:							

QUICK SEQUENTIAL ORGAN FAILURE ASSESSMENT (SOFA) SCORE

qSOFA (Quick SOFA) Criteria	Points
Respiratory rate ≥22/min	1
Change in mental status (GCS < 15)	1
Systolic blood pressure ≤100 mmHg	1
Total Score	0 - 3

INVESTIGATIONS

Complete Blood Count

- Total Count Cells/cmm
- Differential counts
- Neutrophils % Lymphocytes % Eosinophils % Monocytes % and their absolute values
- HB gm%
- Platelets lakhs/cmm

BIOCHEMISTRY

• Serum Lactate

MICROBIOLOGY

Blood culture

FINAL DIAGONOSIS

P. G. GUIDE: DR. RAVI B PATIL

M.S (GENERAL SURGERY)

PROFESSOR AND HOD

DEPARTMENT OF EMERGENCY MEDICINE

B.L.D.E (DEEMED TO BE) UNIVERSITY

SHRI B. M. PATIL MEDICAL COLLEGE HOSPITAL &

RESEARCH CENTER

VIJAYAPUR, KARNATAKA

ANNEXURE IV

FORMULA FOR CALCULATION OF NLR:

$$NLR = \frac{Absolute neutrophil Count}{Absolute lymphocyte Count}$$

ANNEXURE V

PATIENT MASTER CHART

BASAVABATE AVA BARIER LATE AND LATE AVA BARIER BASEL BARIER BARIERA BASEL BARIERA BARIERA VITTAL BARIER BERLEA	**************************************	100	177000	12 - 10 - 13 12 - 10 - 13	1 10000 1 10000 1 10000	2000 2000 2000 2000	23222 232222 2322222	19.2	1752.3	70.00 0.00 0.00 0.00	22			** Varsperrene
FRANCHAMA BAVEERA VALLARIA BURBA CATE CARACTE LARIA BARACE		1111111	140000	A B - Colored St.		22.2	##VE 4	23	1000 1000 1000 1000 1000 1000 1000	0.00 00.00 00.00 00.00 00.00 00.00	2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -	FIGURE AND ADMINISTRATION OF THE PROPERTY OF T	11111	VALGERIALER
	- 11	É	131707	22/22/11	2 2222	## 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10	20000	2.2	1000	0.00	- 11	F. S. TARIA M. S. TARIALA M. S. TARIALA S. TARIALA M. S. TARIALA	1	VALOFIELDS VALOFIELDS
	- 22	2	110107	COC SE	2 5000	12.2	20700	15.5	2000	211	111	A STREET, STRE	11	** VANSFILLERI
JARAFE BURGARAN	25	412214	10407 10407 10404 10404 10404 10404 10404 10404			88.5	7000 0 2000 0 2000 0 1000 0 1000 0 1000 0 1000 0 1000 0	22	11111	22.00	- 11	B - STREET BY BE STREET	1	VALORIELLOS
THE RESIDENCE OF THE PARTY OF T		1	122222	BUI	1 10750	20.0		- 55	1100.5	20.00	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	B. STARTER AND THE STARTER AND	E.	VALORES OF
LUANTE DI MARIE SERIAS MES	44 44 44 44 44 46 46 46 46 46 46 46 46 4	Manna Manna	10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	20 11 11 11 11 11 11 11 11 11 11 11 11 11	10010	97.2 97.2 97.2 97.2 97.2 97.2	**************************************	22	100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	- 5 5	The control of the co	111	VALORETTE
ASSISTANCE OF THE STATE OF THE	58	E	200730	100.00	2 20220	10.0	27020 0	- 53	305.79	22.22	11	M.STRILLE, D. BERTHER STREET	1	VALGERESSER
SUMMERS OF STREET	25	É	107100	100.22	10000	10.5	22222.7	2.5	1202.5	2.72	11	B-PS-EMILE PROPERTY	1	VASCREENS
CONTROL CONTRO	- 22	8	101011	100.00	2 2000	22.5	24400.0		153.72	77.27			1	VASOFRESSON VASOFRESSON VASOFRESSON
MILETINGE VALARIA	25 25 25 25 25	É	212222 212222 212222 212222		2 20370 2 2030 2 2030 2 2030	00 to	2740.0 2740.0	0.0 0.0 0.0 0.0 0.0	222.00 100.1	# 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	1.5	#	111	VARREBERRE
TVAC MARKE BLACK AND MARKET	48	6.0	222000	100.00	1 10000	95.5	22074.2	- 51	1001	10.00	- 11	M - 5 T B H L B; M - 5 T B H L B; M - 5 T B H L B; M - 5 T B H L B;	-	VALORESTANDS
The second secon	20 20 20 20 20 20 20 20 20 20 20 20 20 2	E.	# # 1 # 1 # 1 # 1 # 1 # 1 # 1 # 1 # 1 #	111111111111111111111111111111111111111	1	70.0	10 00 00 00 00 00 00 00 00 00 00 00 00 0	22	200 - 0 200 -	\$ 10 - 10 10 \$ 2 - 10 - 10 \$ 2 - 1	21	M - N-TH HILL II. II. III. III. III. III. III.	111	TALEFEETER
JAMES BOLL TOLL	25	I	222222		1 1000	25.0	7500 A	22	1222	7.44	2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	M. W. C.	1	VANCETERS 0.00
PARTITION THROUGH THE LANGE OF	22	- 23	100001		2 10230 2 10230 2 11570	22.2	2000.22	3.5	202.01	3 32	2.5	E STEELS	2	VANDERSSON
**************************************	27	HIMININ.	222023				2000.17 2000.17	5.2	201.01 200.21 200.21		11	AL - IN THE REAL PARTY OF THE P	1	VASSPRESS SE VASSPRESS SE VASSPRESS SE
SARAN PARAMETER	22	2	120012		1 1000	22.2 22.2	22207.2	2.2	1007.1	3 22	2.2	MANUFACTURE OF A LANGE	1	VARIFFERE
PARTON TO BE ACTOR	30	-	200000	200.00	1 10000	90.0	27444	200	2000.0	10.70	12.2	B. STARTE AND READ AND A STARTED AND A START	-	T SALEFBELLES
**************************************	- 11	200	201201		1 10000	20.0	100000	2 - 1 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -	1551	111	- 11	The second secon	1	
RANGE TAYYA DAGTA	100 100 100 100 100 100 100 100 100 100	653		A11 32 32 32 32 32 32 32 32 32 32 32 32 32		22.2	2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4			Section 1		HE STREET, SECOND STR	1	VANDED BANDS
tutologo, noncert	21	-	HARLA HARLA			######################################	10 V 10 W V 10 W 10 W 10 W 10 W 10 W 10	111	200 A	11.11	- 11		111	VALEFBELLER
The second of th	25		1001712	M32 33	1 11000	20.2	22227.22	12.2	10000	2.12	111	M - M - M M M M M M M M M M M M M M M M	1	VANDERESS CO.
BENEFIT STATES	- 55	2	100000	200.00	1 1110	111	2027.12	200	111111	22.2	11	B-STERLE, M. BATER DESCRIPTION OF SERVICES AND SERVICES A	1	VANDERSSON
HARAMAN BARRELAN RABAR	22	2	10000	22.11	2100	72.2	10 10 10 10 10 10 10 10 10 10 10 10 10 1	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1000 5	122	2.2	A CONTROL OF THE CONTROL OF T	1	VANDERSANDS
BUSEPA SIBBEPA TAMAR	22	÷	100000	200-00	1 10000	55.2	148124	22	22222	37.0	===	No. 16 T B 1 1 L M 1 Lat. 20 A P B 1 L M 1 M 1 L M T B 1 L M 1 M 1 L M T B 1 L M 1		VALORITATION
SANGEAT MANGE		8	110017	200 22	1 11750	200	4444	12.0	400.00	2.54	2.2	E- E		VANDERSSON
MARKATANA BUARTANIAN	20 20 20 20 20 20 20 20 20 20 20 20 20 2	ž	110000	20111	1 10000	20.5	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	24 A	1400.4	10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	11	W. S. C. S. C. C.		VALORESSON
EASTERNATION AND AND AND AND AND AND AND AND AND AN	55	į.	111111		# ####################################	20.0	100000	10.0	1102.2	2.22	11	March 19 The State of the State	1	
BARRERS BARRARES	20		110100	200	2 2250	90.0	20222 C	20.5	1012 1	22.22	2.1	Market Market - Market Market - Market Market Market - Market	-	VALORIESSON
The second deposits the first of the case	### ### #### #########################	22.47.	100000 100000 100000 100000 100000 100000 100000 100000	280.00	1 11110	92.5	## 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	27.5 27.5 27.5 27.5 27.5 27.5 27.5 27.5	# 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0.00 0.00 0.00 0.00 0.00	2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		2	VALORIELESS VALORIELESS
SINGESTAL FORMAN	- 22	2	220020	May 22	Section 1	22.5	2222.53	200	*****	222	- 11	B 5 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	11.11	
BRITISH OF BASES FA	25	-111-1111	241548 241548 241548 241548	NACO SE NACO S	1 17000	22.2	1111111	35	203.23	22.22	- 11	M. D. T. B. C. B.	1	VASOFFESSOR
VAMANAI SHANKAR BHATABE	33	2	22222	MAN SE	13138	99.5	113007		1222	1.14 1.14 1.14 1.14 1.14 1.14 1.14 1.14	2.5	Martin Table 1 Late 1 Martin Late 1 Martin Late 1 L		VASSERESSEE
A STATE OF THE STA	- 22	Ė	111111	20111		22.2	222222			2.23		SI - SI ON BE SI AND SI - SI Y SI SI AND SI - SI Y SI SI AND SI - SI Y SI SI AND	-	×22.00000000000000000000000000000000000
HARAMAN VARABAREA BARURAY SIRRARAA BIRARAR BARURAY SIRRARAA BIRARAR	22	2.8	11000	00-01 - 0 0 00-01 - 0 0	111111	92.2	\$ 5 00 00 00 00 00 00 00 00 00 00 00 00 0	12.2	1000.5	5.25	0. V 0. V 0. V 0. V 0. V 0. V	White British and the second s	1	OAS IN HESS IN
PROPERTY OF STATES	- 25	1	22222	2011	1 11111	12.2	11111111	17.3	2000.0	1.51	- 11	Mark The Control of t	1	VANGERESSON
ALLONATION MAD US	22	2.5	212122	000 01 000 01	1 10000	22.5	12140.2	223	220.02	2.22	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	B. STREET, D. STREET, S. S. STREET, S. STREET, S. S. ST	111	VARREEREE
SALE TO BE A SALE OF A SAL	- 88	ä	A COLUMN TO THE PARTY OF THE PA		5555	22.5	0217.72	3.2	11170	2.00	- 55	10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	12	- VALSFELLSE VALSFELLSE
ANALYSIS AND STATES	- 22	2	101011	80.11	2 2000 2 2000 2 2000 2 2000 2 2000 2 2000 2 2000	22.2	100000	22.0	11177	20.00	2.2	B-STERILE, SELECTOR STERILE BACKETER SETER	-	VA500000000
PARTICIPANT AND THE RESIDENCE OF THE PARTICIPANT OF	38	E	100101	100 II	1 1000		7444 6 7444 6	10.5	100011	2.00	1.1	Market Market, Market Sanction	1	VALORIESSON
ADDRESS OF THE PARTY OF THE PAR	22	1	11000	111.11	2 22220	25.5	17171	200	1555.1	2.00	13	TO SERVICE TO SER	1	VALORESSON
BARAGA BARAGEA		111111111111111111111111111111111111111	11111	Secretary of the secret	# 10000 # 10000 # 10000 # 10000 # 10000 # 10000	000 10 10 10 10 10 10 10 10 10 10 10 10	2722.20	12.7	200.0		1.5	10 - 5 THE LEE	1	**********
BILLY BALAC BEARBARAYYA S BUAYLAATU BULARTA BUASARAR	22		22222			1111		24.7	1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		1 1	M. D. T. M. M. L. L.	Ē,	VALSFILLE
LEGISTIC CONTROL OF THE PARTY O	25		22115	100.00	12320	77 L	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			10.00	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	M. D. THE STATE OF	1	VALSFILLER
MANAGED B STATES	70 044 44 40 40 40 40	111111111111111111111111111111111111111	21222 2222 2222 2222	For any of the second s	S STATE	1111	100000	- 11	444.4 444.4 444.4 444.4 444.4 444.4 444.4	30.35	25	- STREET, M. STREET,	1	VALORIELLAI
THAT SEVERE BASEFEA	- 11	2			10070	101	222222	22	1271.5	20.10 21.77 1.07	3.5	m. arministra, printa la la manta de la manta del manta de la manta de la manta del manta de la manta del manta de la manta del manta de la manta del ma	1	
TO SEE STANDARD TO SEE STANDAR	90 90 90 90 90 90	unun,	20001	May 31 May 31 May 31	2 10000 2 10000	92 1 94 1 94 1 94 1 94 1	177200	111	100 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	20 24 20 24 20 25 20 25	1.0	ESSENIES ESSENIES IN SERVICE		**************************************
DEBLORDS BALLARES	22	2	40044	287: 53 887: 58	1 17110	1111	100000	111	10000	92.22	3.3	H. STREET, STR	1111	VARIENTERS
	20 20 20 20 20 20 20 20 20 20 20 20 20 2	MIL HILL	12010	Approximately	- 100 MA	22.2 22.3 22.3	1	77.7	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	# 10 - 0 - 0 # 10 - 0 - 0		TO SERVICE OF THE PROPERTY OF	1	VANCERDANCE
MANUAL TANDAM ANALES	32	22	110775	111111	1 11100		110011	2.5	1077.7	1111		E-STEELS OF STEELS	111	VALORIES OR VALORIES OR VALORIES OR
BAPPA BANG APPA TOBALDANI	22	2	22100	120.21	22270	00 - V	201012	7,0	125741	7.2	2.5	M - 6 THE STATE OF		TARREST OF THE PARTY OF THE PAR
MARKET E AVAT	- 11		101111	100 0 1 100 0 1 100 0 1 100 0 1		25.4	100000	200	277.77	B. Cont. (1) (1) (2) (2) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4	2:0	M. STREET, M. STREET,	1	VALOFIELLS
The property of the property o	22	111111111111111111111111111111111111111	200755			11.5	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	31	110.00	22.22	22	H-STREET, CONTROL STREET, SALES STREET, SALE	1	VALSERILLES
ALLAFFA HARAFFA WARLAN	11	2	27765	216 11	7,400	200	20207.2	100	222742	10.10	2.5	H-STERLE, DISCHARGE STREET		VALSFILLES
CHARLES SHOWN THE COLUMN	22	2	272275	218-11	10 (0.00 cm.)	22.5	V2440		1000	1111	25	HOLES OF THE STATE	8	VALORES
Marianan Pomanana Tavata narusu kawas	- 11	1221-12	222722	200 11		100	70000 00000 00000	22.2	100 00 100 00 10	122	3.5	M - N THE STATE OF		VALUEBRASH
LANGERANI BALVANI LANGERANTHI BALVANI LANGER THE BALVANI	35	200	200011	212 22	2 2000		2001.00	22.2	11200	2.55	111	M. STREET, MAS. STREET, STREET	1	
The state of the s	200 200 200 200 200 200 200 200 200 200		101101 101101 101101	0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	STATES OF THE ST	### ### #### #########################	\$ 2.00 mm or 10 mm or	10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	\$ 100 mm and \$ 100	# 1	5.3	The second secon		VALUETIES
IS ASSESSED TO A SECOND PROPERTY OF THE PROPERTY PARTY PROPERTY OF THE PROPERT	12	8	121222	100.00	11111	911	101117	350	24.11	11.71	18	H. STREET, D. STREET,	1	VASSPRESSER
PARAGETA AMARAYA	53	44.5	111111	125 22	20000	22.5	170000	22	1017.0	12.72		March 1990 Annie 1990	1	VALHERITER
	22	20.00	122222	to a product to a		11.2	1	11	222.22	2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00	2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -	The second secon		VALEFIELEE
Javanasan No. 2 215 avva	2.2	-	Isanat	21-5009	1 18218	40.00	-7555.5	57.5	22222	2.72	2.2	0 - 5 THE ST. I	1 2	VASOFFESSOR



Document Information

Analyzed document RK Thessis final for submission 2022 (4).docx (D151189777)

Submitted 11/28/2022 6:33:00 AM

Submitted by Somu

Submitter email somulalasangi@gmail.com

Similarity 7%

Analysis address somulalasangi.blde@analysis.urkund.com

Sources included in the report

SA	Urkund.docx Document urkund.docx (D123742526)	88	2
W	URL: https://www.researchgate.net/publication/327015377_Sepsis_3_and_the_burns_patient_do_we_need_S Fetched: 10/23/2019 1:52:58 PM	88	3
SA	11552.docx Document 11552.docx (D123742788)	88	3
SA	3 JESME PAUL GENERAL SURGERY.docx Document 3 JESME PAUL GENERAL SURGERY.docx (D125566716)	88	1
SA	Rishabh REVIEW OF LITERATURE FINAL.docx Document Rishabh REVIEW OF LITERATURE FINAL.docx (D110854002)	88	1
SA	EOSINOPENIA AS A DIAGNOSTIC MARKER OF SEPSIS IN CRITICALLY ILL PATIENTS ADMITTED TO COIMBATORE MEDICAL COLLEGE HOSPITAL.docx Document EOSINOPENIA AS A DIAGNOSTIC MARKER OF SEPSIS IN CRITICALLY ILL PATIENTS ADMITTED TO COIMBATORE MEDICAL COLLEGE HOSPITAL.docx (D122188348)	88	1
SA	22Final Naveen thesis 26.1.22 without masterchart.docx Document 22Final Naveen thesis 26.1.22 without masterchart.docx (D126355546)	88	2
W	URL: https://emcrit.org/pulmcrit/nlr/ Fetched: 11/20/2019 2:03:38 AM	88	11